Journal of Hand Therapy
Volume 23, Issue 2 , Pages 230-237 , April 2010

Medication-induced Adverse Effects: Important Concepts for the Hand Therapist

  • Daniel M. Riche, PharmD, BCPS, CDE

      Affiliations

    • Corresponding Author InformationCorrespondence and reprint requests to Daniel M. Riche, PharmD, BCPS, CDE, Department of Pharmacy Practice and Medicine, University of Mississippi Medical Center, Office Annex Building, WW 120-A, 2500 North State Street, Jackson, MS 39216

References 

  1. Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed. 2007;9:58
  2. Siris ES, Selby PL, Saag KG, Borgström F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009;122(Suppl 2):S3–S13
  3. Lamb E. Top 200 prescription drugs of 2008. Available at: http://www.pharmacytimes.com/issue/pharmacy/2009/2009-05/RxFocusTop200Drugs-0509Accessed 15 May 2009
  4. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008;31:53–65
  5. Mastaglia FL. Adverse effects of drugs on muscle. Drugs. 1982;24:304–321
  6. Palmucci L, Bertolotto A, Doriguzzi C, Mongini T, Ardizzone G. Myoglobinuria: presentation of personal cases and review of the literature. Ital J Neurol Sci. 1981;2:275–282
  7. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol. 2007;18:401–408
  8. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA. Genetic determinants of statin intolerance. Lipids Health Dis. 2007;6:7
  9. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585–2590
  10. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119:400–409
  11. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol. 2002;42:963–970
  12. O-Lee T, Stewart CE, Seery L, Church CA. Fluoroquinolone-induced arthralgia and myalgia in the treatment of sinusitis. Am J Rhinol. 2005;19:395–399
  13. Melhus A. Fluoroquinolones and tendon disorders. Expert Opin Drug Saf. 2005;4:299–309
  14. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49:2231–2237
  15. Riche DM, Valderrama R, Henyan NN. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis. Diabetes Care. 2007;30:384–388
  16. Schwartz AV. TZDs and bone: a review of the recent clinical evidence. PPAR Res. 2008;2008:297893
  17. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces changes in bone mass and strength that are reminiscent of aged bone. Endocrinology. 2007;148:2669–2680
  18. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007;92:1305–1310
  19. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2008;93:1696–1701
  20. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91:3349–3354
  21. Kahn S, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–2443
  22. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168:820–825
  23. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125–2135
  24. Spanheimer R, Takeda Pharmaceuticals North America, Inc . Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS® (pioglitazone HCl) tablets for type 2 diabetes mellitus. Available at: http://www.fda.gov/medwaTCH/safety/2007/Actosmar0807.pdfAccessed 9 Mar 2007
  25. Zizic TM, Marcoux C, Hungerford DS, Dansereau JV, Stevens MB. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med. 1985;79:596–604
  26. Felson DT, Anderson JJ. Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet. 1987;1:902–906
  27. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32:94–124
  28. Pullatt RC, Gadarla MR, Karas RH, Alsheikh-Ali AA, Thompson PD. Tendon rupture associated with simvastatin/ezetimibe therapy. Am J Cardiol. 2007;100:152–153
  29. Marie I, Delafenetre H, Massy N, Thuillez C, Noblet C. Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature. Arthritis Rheum. 2008;59:367–372
  30. Beri A, Dwamena FC, Dwamena BA. Association between statin therapy and tendon rupture: a case-control study. J Cardiovasc Pharmacol. 2009;53:401–404
  31. Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(Suppl 2):S144–S157
  32. Kuehn BM. Floroquinolone warning. JAMA. 2008;300:891
  33. Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother. 2007;41:1859–1866
  34. Kato M, Takada S, Kashida Y, Nomura M. Histological examination on Achilles tendon lesions induced by quinolone antibacterial agents in juvenile rats. Toxicol Pathol. 1995;23:385–392
  35. Förster C, Kociok K, Shakibaei M, Merker HJ, Stahlmann R. Quinolone-induced cartilage lesions are not reversible in rats. Arch Toxicol. 1996;70:474–481
  36. Lim S, Hossain MA, Park J, Choi SH, Kim G. The effects of enrofloxacin on canine tendon cells and chondrocytes proliferation in vitro. Vet Res Commun. 2008;32:243–253
  37. Pratt RW, Weimer LH. Medication and toxin-induced peripheral neuropathy. Semin Neurol. 2005;25:204–216
  38. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96:23–43
  39. Anstead GM. Steroids, retinoids, and wound healing. Adv Wound Care. 1998;11:277–285
  40. Zitelli J. Wound healing for the clinician. Adv Dermatol. 1987;2:243–267

PII: S0894-1130(09)00155-0

doi: 10.1016/j.jht.2009.12.001

Journal of Hand Therapy
Volume 23, Issue 2 , Pages 230-237 , April 2010

Article Tools